• Login
    JavaScript is disabled for your browser. Some features of this site may not work without it.
    Search 
    •   QMRO Home
    • Search
    •   QMRO Home
    • Search
    ‌
    ‌

    Browse

    All of QMROCommunities & CollectionsBy Issue DateAuthorsTitlesSubjects
    ‌
    ‌

    Administrators only

    Login
    ‌
    ‌

    Discover

    Author
    Giovannoni, G (17)
    Schmierer, K (8)Gnanapavan, S (5)Baker, D (4)Dobson, R (4)Marta, M (4)Thomson, A (4)Turner, B (4)Noyce, AJ (3)Davis, A (2)... View MoreSubject
    Humans (17)
    Multiple Sclerosis (9)Female (8)Male (8)Adult (5)Middle Aged (5)Immunologic Factors (4)Aged (3)Alemtuzumab (3)Disability Evaluation (3)... View MoreDate Issued2022 (1)2020 (2)2019 (3)2018 (3)2017 (4)2016 (2)2015 (2)
    ‌
    ‌

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Search

    Show Advanced FiltersHide Advanced Filters

    Filters

    Use filters to refine the search results.

    Now showing items 1-10 of 17

    • Sort Options:
    • Relevance
    • Title Asc
    • Title Desc
    • Issue Date Asc
    • Issue Date Desc
    • Results Per Page:
    • 5
    • 10
    • 20
    • 40
    • 60
    • 80
    • 100
    Thumbnail

    Atraumatic needles for lumbar puncture: why haven't neurologists changed? 

    Davis, A; Dobson, R; Kaninia, S; Giovannoni, G; Schmierer, K (2016-02)
    Diagnostic lumbar puncture is a key procedure in neurology; however, it is commonly complicated by post-lumbar puncture headache. Atraumatic needle systems can dramatically reduce the incidence of this iatrogenic complication. ...
    Thumbnail

    Marked neutropenia: Significant but rare in people with multiple sclerosis after alemtuzumab treatment. 

    Baker, D; Giovannoni, G; Schmierer, K (2017-11)
    BACKGROUND: Alemtuzumab is a CD52-specific monoclonal antibody that markedly depletes T and B lymphocytes and inhibits relapsing multiple sclerosis (MS). However, polymorphonuclear neutrophils also express CD52 and can be ...
    Thumbnail

    Vitamin D supplementation. 

    Dobson, R; Cock, HR; Brex, P; Giovannoni, G (2018-02)
    Vitamin D testing and supplementation is of great interest to neurologists and their patients. Recommended nutritional intakes of vitamin D in the UK remain focused on bone health, despite increasing evidence for a role ...
    Thumbnail

    Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings. 

    Coles, AJ; Cohen, JA; Fox, EJ; Giovannoni, G; Hartung, H-P; Havrdova, E; Schippling, S; Selmaj, KW; Traboulsee, A; Compston, DAS;... (2017-09-12)
    OBJECTIVE: To evaluate 5-year efficacy and safety of alemtuzumab in patients with active relapsing-remitting multiple sclerosis and inadequate response to prior therapy. METHODS: In the 2-year Comparison of Alemtuzumab and ...
    Thumbnail

    Validation of an environmentally-friendly and affordable cardboard 9-hole peg test. 

    Dubuisson, N; Bauer, A; Buckley, M; Gilbert, R; Paterson, A; Marta, M; Gnanapavan, S; Turner, B; Baker, D; Giovannoni, G;... (2017-10)
    BACKGROUND: In multiple sclerosis (MS) upper limb neurological impairments, are an important driver of disability and handicap. The gold standard for assessing upper limb function is the 9-hole peg test (9HPT). One ...
    Thumbnail

    Switching patients at high risk of PML from natalizumab to another disease-modifying therapy. 

    Giovannoni, G; Marta, M; Davis, A; Turner, B; Gnanapavan, S; Schmierer, K (2016-10)
    There are several options for switching people with multiple sclerosis (MS) who are at high risk of developing progressive multifocal leukoencephalopathy (PML) from natalizumab to alemtuzumab. However, some of these have ...
    Thumbnail

    Developing Biomarkers for MS. 

    Gnanapavan, S; Giovannoni, G (2015)
    Existing clinical outcomes of disease activity, including relapse rates, are inherently insensitive to the underlying pathological process in MS. Moreover, it is extremely difficult to measure clinical disability in patients, ...
    Thumbnail

    No laughing matter: subacute degeneration of the spinal cord due to nitrous oxide inhalation. 

    Keddie, S; Adams, A; Kelso, ARC; Turner, B; Schmierer, K; Gnanapavan, S; Malaspina, A; Giovannoni, G; Basnett, I; Noyce, AJ (2018-05)
    BACKGROUND: Whilst the dangers of 'legal highs' have been widely publicised in the media, very few cases of the neurological syndrome associated with the inhalation of nitrous oxide (N2O) have been reported. Here we set ...
    Thumbnail

    Screening performance of abbreviated versions of the UPSIT smell test. 

    Joseph, T; Auger, SD; Peress, L; Rack, D; Cuzick, J; Giovannoni, G; Lees, A; Schrag, AE; Noyce, AJ (2019-08)
    BACKGROUND: Hyposmia can develop with age and in neurodegenerative conditions, including Parkinson's disease (PD). The University of Pennsylvania Smell Identification Test (UPSIT) is a 40-item smell test widely used for ...
    Thumbnail

    The BRAIN test: a keyboard-tapping test to assess disability and clinical features of multiple sclerosis. 

    Shribman, S; Hasan, H; Hadavi, S; Giovannoni, G; Noyce, AJ (2018-02)
    BACKGROUND: The BRadykinesia Akinesia INcordination (BRAIN) test is an online keyboard-tapping test previously validated as a sensitive tool for detecting signs of Parkinson's disease. OBJECTIVES: To determine whether the ...
    • 1
    • 2
    Twitter iconFollow QMUL on Twitter
    Twitter iconFollow QM Research
    Online on twitter
    Facebook iconLike us on Facebook
    • Site Map
    • Privacy and cookies
    • Disclaimer
    • Accessibility
    • Contacts
    • Intranet
    • Current students

    Modern Slavery Statement

    Queen Mary University of London
    Mile End Road
    London E1 4NS
    Tel: +44 (0)20 7882 5555

    © Queen Mary University of London.